AstraZeneca admits rare blood clot risk from covid jabs as it faces class action lawsuit in UK

  • Facing a class action lawsuit in the UK, the drug company acknowledged a rare blood clotting risk from covid jabs.

Priyanka Sharma
First Published30 Apr 2024, 07:07 PM IST
AstraZeneca said that from the body of evidence in clinical trials and real-world data, the AstraZeneca-Oxford vaccine has continuously been shown to have an acceptable safety profile.
AstraZeneca said that from the body of evidence in clinical trials and real-world data, the AstraZeneca-Oxford vaccine has continuously been shown to have an acceptable safety profile.

New Delhi: British drugmaker AstraZeneca admitted covid vaccines could cause blood clots but said these were “extremely rare” after more than 50 such cases were reported in the UK in patients administered jabs that had been made by the Serum Institute of India. 

The company said on Tuesday that patient safety is its highest priority. Regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines, it added.

The pharma company said regulators around the world have consistently stated that the benefits of vaccination outweigh the risks of extremely rare potential side-effects.

The company is facing a class action lawsuit in the UK over allegations its vaccine had caused fatalities and severe injuries in numerous instances. Victims involved in up to 51 cases in the UK High Court are seeking damages totalling up to 100 million pounds.

The vaccine, known by various brand names, including Covishield in India, was developed in the UK and manufactured by SII in India. These vaccines were sold around the world. 

Following the lawsuit, AstraZeneca has expressed sympathy for those affected by adverse reactions to its vaccine.

Also read: AstraZeneca's Covid vaccine can cause ‘TTS in very rare cases': What is it?

AstraZeneca on Monday admitted in a legal filing in the UK that its vaccine can result in a condition known as thrombosis with thrombocytopenia syndrome (TTS) in rare instances. 

TTS involves the formation of blood clots accompanied by a low platelet count, which is crucial for blood clotting.

“It is admitted that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is not known. Further, TTS can also occur in the absence of the AZ vaccine (or any vaccine). Causation in any individual case will be a matter for expert evidence,” the drugmaker said.

Highest priority

“Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines, " it said in a statement on Tuesday.

The company said that from the body of evidence in clinical trials and real-world data, the AstraZeneca-Oxford vaccine has continuously been shown to have an acceptable safety profile.

Also read: COVID-19 Vaccine: Covishield outperforms Covaxin in first-of-its-kind comparative study. Key things to know

Covishield, a vaccine developed by AstraZeneca and Oxford University, was extensively administered to the Indian population.

Recombinant tech

It is a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike (S) glycoprotein. Following administration, the genetic material of part of coronavirus is expressed which stimulates an immune response.

Queries sent to the Serum Institute of India and India’s health ministry remained unanswered.

In 2022, a reputed medical journal Pubmed published a report citing a short-term adverse event following two doses of Covishield, but these were mild and short lived. 

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.MoreLess
First Published:30 Apr 2024, 07:07 PM IST
HomeCompaniesNewsAstraZeneca admits rare blood clot risk from covid jabs as it faces class action lawsuit in UK

Most Active Stocks

Tata Steel

168.25
01:12 PM | 16 JUL 2024
1.45 (0.87%)

Oil & Natural Gas Corporation

323.80
01:12 PM | 16 JUL 2024
1.25 (0.39%)

Coal India

514.00
01:12 PM | 16 JUL 2024
16.05 (3.22%)

ICICI Bank

1,242.00
01:12 PM | 16 JUL 2024
11.75 (0.96%)
More Active Stocks

Market Snapshot

  • Top Gainers
  • Top Losers
  • 52 Week High

Alembic Pharmaceuticals

1,067.75
01:05 PM | 16 JUL 2024
85.2 (8.67%)

Tata Teleservices Maharashtra

81.82
01:05 PM | 16 JUL 2024
4.72 (6.12%)

JM Financial

100.60
01:05 PM | 16 JUL 2024
5.57 (5.86%)

K P R Mill

879.25
01:05 PM | 16 JUL 2024
45.7 (5.48%)
More from Top Gainers

Recommended For You

    More Recommendations

    Gold Prices

    • 24K
    • 22K
    Bangalore
    74,318.00-453.00
    Chennai
    74,755.00928.00
    Delhi
    75,266.001,294.00
    Kolkata
    75,047.001,002.00

    Fuel Price

    • Petrol
    • Diesel
    Bangalore
    102.86/L0.00
    Chennai
    100.76/L0.01
    Kolkata
    104.95/L0.00
    New Delhi
    94.72/L0.00
    OPEN IN APP
    HomeMarketsCibilPremiumMint Shorts